Krems an der Donau, Austria, 22nd July 2014 – Lacerta Technologies has published a research article in cooperation with Semmelweis University and Singapore Bioimaging Consortium in the Journal “Biomed Research International”.
Local antibiotics in connection with bone substitutes are usually applied to prevent primary infections, implanted into a contaminated area or eliminate recurrent infection. These cases all have their requirements in terms of choice of antibiotics and length of release time, so there is no uni-versal coating technique for all cases. Dr. Hornyák, principle investigator of this study and his team aimed to develop a sustained-release coating for bone allografts, which can achieve long-term characteristics for several antibiotics.
Simply adding antibiotics or freeze-drying them onto the allograft only reaches a 2-day release profile, which is even shorter than the closure time of the surgical wound. Insoluble alginate coat-ing achieved a sustained release of each selected antibiotic to various lengths, depending on the physicochemical characteristics of the drugs. Amoxicillin may be applicable for primary prevention while ciprofloxacin or vancomycin is suitable for more challenging cases.
Link to the article: http://www.ncbi.nlm.nih.gov/pubmed/25045678
Profile Lacerta Technologies GmbH
Founded in 2012 and located in Krems an der Donau/Austria Lacerta Technologies GmbH is a clinical-stage regenerative medicine company aiming to translate research results into products for routine clinical use. We put special emphasis on designing simple and affordable protocols allowing a wider patient population to benefit from cell therapy.
Our current development projects include an innovative albumin-coated bone allograft and a point-of-care device for the personalised production of autologous serum products.
Lacerta Technologies GmbH
A-3500 Krems an der Donau
Tel/Fax: +43 664 77 883 16206